Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421396 | 0.92 | GAA (0.35) | GAAKDM4EMAPTLMNAPAX8 | |
| SCHEMBL421157 | 0.90 | KDM4E (0.34) | GAAKDM4EMAPTLMNAPAX8 | |
| SCHEMBL420102 | 0.89 | CNR2 (0.34) | GAAKDM4EMAPTLMNAPAX8 | |
| SCHEMBL419132 | 0.89 | TUBB4A (0.33) | GAAKDM4EMAPTLMNAPAX8 | |
| SCHEMBL420105 | 0.89 | CDC25A (0.35) | GAAKDM4EMAPT | |
| SCHEMBL420062 | 0.86 | KDM4E (0.35) | GAAKDM4EMAPTLMNAPAX8 | |
| SCHEMBL419087 | 0.85 | HSP90AA1 (0.38) | HSP90AA1MPOHTR2CCYP19A1 | |
| SCHEMBL443161 | 0.84 | KDM4E (0.32) | GAAKDM4EMAPTLMNAPAX8 | |
| SCHEMBL419112 | 0.83 | KDM4E (0.33) | GAAKDM4EMAPTLMNAPAX8 | |
| SCHEMBL1147429 | 0.83 | KDM4E (0.33) | GAAKDM4EMAPTLMNAPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP (US) | 2016-05-05 | — | — | US | disclosed |
| US-9205086-B2 | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205086-B2 | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140363830-A1 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140363830-A1 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20130150385-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150385-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120245186-A1 | COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245186-A1 | COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8188075-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188075-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-7825148-B2 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825148-B2 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | disclosed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120849-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | EGFR, HSP90AB1, HSP90AA1 | GAA 930/4885KDM4E 3747/4885MAPT 34/4885 |
| US-20120245186-A1 | COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90B1, HSP90AA1 | GAA 813/4885KDM4E 4589/4885MAPT 49/4885 |
| US-20130150385-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | EGFR, HSP90AB1, HSP90B1 | GAA 753/4885KDM4E 3942/4885MAPT 45/4885 |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | HSP90AB1, HSP90AB2P, HSP90AA1 | GAA 320/4885KDM4E 2879/4885MAPT 2568/4885 |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | GAA 1169/4885KDM4E 3814/4885MAPT 1902/4885 |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | GAA 543/4885KDM4E 4422/4885MAPT 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.